DOI: 10.1097/mpa.0000000000002335 ISSN: 1536-4828

THE ADDED VALUE OF BLOOD GLUCOSE MONITORING IN HIGH-RISK INDIVIDUALS UNDERGOING PANCREATIC CANCER SURVEILLANCE

Aleksander M. Bogdanski, Anke M. Onnekink, Akin Inderson, Bas Boekestijn, Bert A. Bonsing, Hans F.A. Vasen, Jeanin E. van Hooft, Jurjen J. Boonstra, J. Sven D. Mieog, Martin N.J.M. Wasser, Shirin Feshtali, Thomas P. Potjer, Derk C.F. Klatte, Monique E. van Leerdam
  • Endocrinology
  • Hepatology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
Show PDF Cite

Abstract

Objectives

The study aimed to investigate the added value of blood glucose monitoring in high-risk individuals (HRIs) participating in pancreatic cancer surveillance.

Methods

HRIs with a CDKN2A/p16 germline pathogenic variant (PV) participating in pancreatic cancer surveillance were included in this study. Multivariable logistic regression was performed to assess the relationship between new-onset diabetes (NOD) and pancreatic ductal adenocarcinoma (PDAC). To quantify the diagnostic performance of NOD as a marker for PDAC, receiver operating characteristic curve with area under the curve (AUC) was computed.

Results

In total, 220 HRIs were included between 2000-2019. Median age was 61 (IQR 53-71) years and 62.7% of participants were female. During the study period, 26 (11.8%) HRIs developed NOD, of whom 5 (19.2%) later developed PDAC. The other 23 (82.1%) PDAC cases remained NOD-free. Multivariable analysis showed no statistically significant relationship between NOD and PDAC (OR 1.21; 95% CI, 0.39-3.78) and four out of five PDAC cases appeared to have NOD within three months before diagnosis. Furthermore, NOD did not differentiate between HRIs with- and without PDAC (AUC 0.54; 95% CI, 0.46-0.61).

Conclusions

In this study we found no added value for longitudinal glucose monitoring in CDKN2A PV carriers participating in an imaging-based pancreatic cancer surveillance program.

More from our Archive